Spinifex Pharmaceuticals, an Australian pain drug development company, has reported that the Phase II trial of EMA401, for the treatment of postherpetic neuralgia (PHN), met its primary endpoint.

The primary endpoint of the placebo-controlled randomised trial was the reduction in mean daily pain score versus a placebo over the last week of 28 days of treatment.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Existing therapies for PHN, which can develop following herpes zoster (shingles), do not relieve pain in all patients.

The study principal investigator Dr Milton Raff said the headline results show clear pain reduction and a good safety and tolerability profile.

“EMA401 offers an entirely novel approach to the treatment of PHN and could represent a valuable new option in an area where there is a clear need for new medicines,” Dr Raff said.

“Current treatments for the condition are effective in some patients but a significant proportion either don’t respond to therapy and are left with debilitating symptoms or suffer significant side effects.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to study results, a statistically significant and clinically meaningful reduction in mean pain intensity from baseline to week four for subjects on active treatment was observed.

The study also met its secondary endpoint by demonstrating a significantly greater proportion of patients on active treatment reported more than 30% reduction in pain.

No serious treatment-related adverse events were observed and EMA401 was generally safe and well tolerated in the study.

Spinifex Pharmaceuticals CEO Tom McCarthy said; “We look forward to advancing EMA401 further in PHN and other neuropathic pain indications including cancer chemotherapy induced neuropathic pain and painful diabetic neuropathy.”